❇️ Cerebrolysin Cerebrolysin is a porcine-derived peptide preparation rich in neurotrophic factors and amino acids. Its neuroprotective and neurotrophic actions stem from constituents such as BDNF, NGF, CNTF, GDNF, P-21, enkephalins, and orexin, making it a versatile tool for neurological research. ❇️ Overview Pharmacodynamics and neurotrophic profile Cerebrolysin’s pharmacodynamic profile mirrors endogenous neurotrophic factors. It supports neuronal survival, fosters synaptic plasticity, and provides neuroprotection—traits that underpin its use across neurodegenerative and neurotraumatic research. ❇️Cerebrolysin is a porcine brain‑derived peptide preparation containing low‑molecular‑weight neuropeptides and free amino acids that crosses the blood–brain barrier to support neuronal survival[1]. It mimics endogenous neurotrophic factors (e.g., NGF, BDNF) and modulates neuroinflammatory mediators[1][2]. This educational protocol presents a once‑daily subcutaneous approach using a practical dilution for clear insulin‑syringe measurements. - Reconstitute: Add 3.0 mL bacteriostatic water → 20 mg/mL concentration. - Typical daily range: 20–32 mg once daily (gradual titration); split doses for >20 mg. - Easy measuring: At 20 mg/mL, 1 unit = 0.01 mL = 200 mcg (0.2 mg) on a U‑100 insulin syringe. Storage: Lyophilized at room temperature ≤25 °C (≤77 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F) and use within 7 days; do not freeze. Standard / Gradual Approach (3 mL = 20 mg/mL) Dosage: Week 1 20 mg (20,000 mcg) 100 units (1.0 mL) × 1 Week 2 24 mg (24,000 mcg) 60 units (0.6 mL) AM + 60 units (0.6 mL) PM Week 3 28 mg (28,000 mcg) 70 units (0.7 mL) AM + 70 units (0.7 mL) PM Week 4+ 32 mg (32,000 mcg) 80 units (0.8 mL) AM + 80 units (0.8 mL) PM ❇️ Frequency: Inject once or twice daily subcutaneously as shown above. Doses exceeding 100 units (1.0 mL) should be split into AM and PM administrations. Clinical literature describes daily doses ranging from 215 mg (1 mL of commercial solution) up to higher IV infusions[1]; this protocol uses a conservative subcutaneous approach with gradual titration.